Sernova (TSE:SVA) Issues Earnings Results

Sernova (TSE:SVA – Get Free Report) announced its quarterly earnings results on Thursday. The company reported C($0.01) EPS for the quarter, FiscalAI reports.

Sernova Price Performance

Sernova stock opened at C$0.14 on Friday. The company has a debt-to-equity ratio of -25.45, a current ratio of 0.14 and a quick ratio of 18.11. The company has a market capitalization of C$52.87 million, a PE ratio of -3.50 and a beta of -0.43. Sernova has a one year low of C$0.10 and a one year high of C$0.20. The business has a 50 day simple moving average of C$0.12 and a 200 day simple moving average of C$0.14.

Get Sernova alerts:

Sernova Company Profile

(Get Free Report)

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.

Further Reading

• Five stocks we like better than Sernova
• AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
• Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
• 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
• Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle

Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.